ZA201308329B - Radiolabelled glutaminyl cyclase inhibitors - Google Patents

Radiolabelled glutaminyl cyclase inhibitors

Info

Publication number
ZA201308329B
ZA201308329B ZA2013/08329A ZA201308329A ZA201308329B ZA 201308329 B ZA201308329 B ZA 201308329B ZA 2013/08329 A ZA2013/08329 A ZA 2013/08329A ZA 201308329 A ZA201308329 A ZA 201308329A ZA 201308329 B ZA201308329 B ZA 201308329B
Authority
ZA
South Africa
Prior art keywords
glutaminyl cyclase
cyclase inhibitors
radiolabelled
radiolabelled glutaminyl
inhibitors
Prior art date
Application number
ZA2013/08329A
Other languages
English (en)
Inventor
Ulrich Heiser
Daniel Ramsbeck
Hans-Ulrich Demuth
Original Assignee
Probiodrug Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiodrug Ag filed Critical Probiodrug Ag
Publication of ZA201308329B publication Critical patent/ZA201308329B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ZA2013/08329A 2011-05-27 2013-11-06 Radiolabelled glutaminyl cyclase inhibitors ZA201308329B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161490654P 2011-05-27 2011-05-27
PCT/EP2012/059649 WO2012163773A1 (en) 2011-05-27 2012-05-24 Radiolabelled glutaminyl cyclase inhibitors

Publications (1)

Publication Number Publication Date
ZA201308329B true ZA201308329B (en) 2015-02-25

Family

ID=46149465

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/08329A ZA201308329B (en) 2011-05-27 2013-11-06 Radiolabelled glutaminyl cyclase inhibitors

Country Status (14)

Country Link
US (2) US8945510B2 (enExample)
EP (1) EP2714098A1 (enExample)
JP (1) JP2014515364A (enExample)
KR (1) KR20140028076A (enExample)
CN (1) CN103561776B (enExample)
AU (1) AU2012264951A1 (enExample)
BR (1) BR112013030341A2 (enExample)
CA (1) CA2835014A1 (enExample)
EA (1) EA028533B1 (enExample)
IL (1) IL229187A (enExample)
MX (1) MX2013013946A (enExample)
SG (2) SG194770A1 (enExample)
WO (1) WO2012163773A1 (enExample)
ZA (1) ZA201308329B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210091830A (ko) 2013-03-15 2021-07-22 비보리온 테라퓨틱스 아게 신규한 억제제
CN104230778B (zh) * 2014-07-14 2017-01-04 大连大学 β-烃氧酰基-γ-烃基-N-烃基-γ-丁内酰胺的合成方法
MY195016A (en) 2014-08-04 2023-01-03 Nuevolution As Optionally Fused Heterocyclyl-Substituted Derivatives of Pyrimidine Useful for The Treatment of Inflammatory, Metabolic, Oncologic and Autoimmune Diseases
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
WO2020023782A1 (en) 2018-07-27 2020-01-30 Biotheryx, Inc. Bifunctional compounds as cdk modulators
KR102230832B1 (ko) * 2019-06-17 2021-03-24 (주) 메디프론디비티 N-치환된 티오우레아 또는 우레아 유도체 및 이를 유효성분으로 함유하는 글루타미닐 사이클레이즈 활성 관련 질환의 예방 또는 치료용 약학적 조성물
AU2020405446A1 (en) 2019-12-20 2022-05-26 Nuevolution A/S Compounds active towards nuclear receptors
BR112022012205A2 (pt) 2019-12-20 2022-09-13 Nuevolution As Compostos ativos para receptores nucleares
CA3174252A1 (en) 2020-03-31 2021-10-07 Nuevolution A/S Compounds active towards nuclear receptors
JP7713954B2 (ja) 2020-03-31 2025-07-28 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物
EP4143329A4 (en) 2020-04-28 2024-10-16 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL302387A (enExample) 1963-01-09
US5304367A (en) * 1990-11-16 1994-04-19 New York University In vivo brain imaging agent and method for diagnosis of psychiatric disorders
US7732162B2 (en) * 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
WO2005075436A2 (en) * 2004-02-05 2005-08-18 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
WO2007124345A2 (en) 2006-04-21 2007-11-01 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Beta-amyloid pet imaging agents
US8278345B2 (en) * 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
EA025107B1 (ru) * 2008-07-31 2016-11-30 Пробиодруг Аг Способ диагностирования болезни альцгеймера, нейродегенерации при синдроме дауна или легкого когнитивного нарушения у субъекта (варианты) и набор для осуществления способа
MX2011002106A (es) * 2008-09-04 2011-04-07 Probiodrug Ag Inhibidores novedosos.
CN102438660A (zh) 2009-03-23 2012-05-02 美国西门子医疗解决公司 用于检测神经障碍的显像剂
PL2475428T3 (pl) * 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).

Also Published As

Publication number Publication date
SG10201604304RA (en) 2016-07-28
US9610368B2 (en) 2017-04-04
US8945510B2 (en) 2015-02-03
US20120301398A1 (en) 2012-11-29
MX2013013946A (es) 2014-01-31
JP2014515364A (ja) 2014-06-30
WO2012163773A1 (en) 2012-12-06
EA201301334A1 (ru) 2014-05-30
AU2012264951A1 (en) 2013-12-12
IL229187A (en) 2017-04-30
KR20140028076A (ko) 2014-03-07
CA2835014A1 (en) 2012-12-06
BR112013030341A2 (pt) 2016-11-29
SG194770A1 (en) 2013-12-30
CN103561776B (zh) 2016-08-31
IL229187A0 (en) 2013-12-31
EP2714098A1 (en) 2014-04-09
NZ617581A (en) 2016-03-31
CN103561776A (zh) 2014-02-05
EA028533B1 (ru) 2017-11-30
US20150104389A1 (en) 2015-04-16

Similar Documents

Publication Publication Date Title
IL273079B (en) Heterocycloamines as pi3k inhibitors
IL229187A0 (en) Radiolabeled glutaminyl cyclase inhibitors
ZA201307016B (en) Glucosylceramide synthase inhibitors
HUE048834T2 (hu) Kináz inhibitorok
ZA201404156B (en) Kinase inhibitors
EP2782580A4 (en) SELECTIVE INHIBITORS OF KINASES
IL229028A0 (en) Kinase inhibitors
GB201009731D0 (en) Kinase inhibitors
ZA201404157B (en) Kinase inhibitors
GB201216884D0 (en) Composition
GB201112157D0 (en) New use of glutaminyl cyclase inhibitors
GB201018597D0 (en) Inhibitors
GB201120474D0 (en) Inhibitors
SG10201602022UA (en) Glucosylceramide synthase inhibitors